Books by Subject

Pharmacy

  • 2016 ClinicalKey
    Betty L. Gahart, Adrienne R. Nazareno, Meghan Q. Ortega.
  • 2012 Wiley
    Alex Avdeef.
    Introduction Transport model pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability -- Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier.
  • 2011 Future Med
    editor, Philip N. Patsalos.
    Advances in antiepileptic drug development / Philip N. Patsalos -- Current guidelines and standard treatments / Dieter Schmidt & G{uml}unter Kr{uml}amer -- Advances in screening models for identifying new antiepileptic drugs / Kinga K. Borowicz & Stanislaw J. Czuczwar -- New antiepileptic drugs : advances in pharmacokinetics, drug interaction and adverse effect profiles / Domenico Italiano & Edoardo Spina -- Antiepileptic drugs in clinical trials and future direction / Alberto Verrotti, Chiara Cirillo & Giulia Loiacono.
  • 2010 Springer
    Jack Uetrecht, editor.
    Pt. 1. Target organ toxicity. -- Drug-induced liver injury / Michael Holt, Cynthia Ju.-- Drug herpersensitivity reactions involving skin / Oliver Hausmann, Benno Schnyder, Werner J. Pichler.-- Adverse drug reactions affecting blood cells / Richard H. Aster.-- Molecular mechanisms of adverse drug reactions in cardiac tissue / Reza Tabrizchi.-- Mechanisms of drug-induced nephrotoxicity / Thomas D. Nolin, Jonathan Himmelfarb.-- Receptor- and reactive intermediate-mediated mechanisms of teratogenesis / Peter G. Wells, Crystal J.J. Lee, Gordon P. McCallum, Julia Perstin, Patricia A. Harper.-- Pt. II. Mediators/Biochemical pathways.-- Role of reactive metabolites in drug-induced hepatotoxicity / A.M. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith, B. K. Park.-- Role of cytokines in the mechanism of adverse drug reactions / Mary Jane Masson, Lindsay A. Collins, Lance R. Poh.-- Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity / Ian M. Copple, Christopher E. Goldring, Neil R. Kitteringham, B. Kevin Park.-- Signal transduction pathways involved in drug-induced liver injury / Derick Han, Mie Shinohara, Maria D. Ybanez, Behnam Saberi, Neil Kaplowitz.-- Mictrochondrial involvement in drug-induced liver injury / Dominique Pessayre, Abdellah Mansouri, Alain Berson, Bernard Fromenty.-- Pt. III. Examples/Models.-- Mechanisms of acetaminophen-induced liver necrosis / Jack A. Hinson, Dean W. Roberts, Laura P. James.-- Drug-induced liver injury in humans: the case of Ximelagtran / M. Keisu, T.B. Andersson.-- Troglitazone / Tsuyoshi Yokoi.-- Neviropine hypersensitivity / M. Popovic, J.M. Shenton, J. Chen, A. Baban, T. Tharmanathan, B. Mannargudi, D. Abdulla, J.P. Uetrecht.-- Mechanisms of adverse drug reactions to biologics / Janet B. Clarke.-- Pt. IV. Risk factors/Screening drug candidates.-- Pharmacogenetics of idiosyncratic adverse drug reactions / Munir Pirmohamed.-- Danger hypothesis applied to idiosyncratic drug reactions / Jinze Li, Jack P. Uetrecht.-- Approaches for minimizing metabolic activation of new drug candidates in drug discovery / Sanjeev Kumar, Kaushik Mitra, Kelem Kassahun, Thomas A. Baillie.
  • 2014 Springer
    Giuseppe Tridente.
    This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered. Electronic data sheets, downloadable from the Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies.
  • 2006 CRCnetBASE
    edited by Norman G. Bowery.
  • by Nicholas Everett.
    The Alphabet of Galen is a critical edition and English translation of a text describing, in alphabetical order, nearly three hundred natural products - including metals, aromatics, animal materials, and herbs - and their medicinal uses. A Latin translation of earlier Greek writings on pharmacy that have not survived, it circulated among collections of 'authorities' on medicine, including Hippocrates, Galen of Pergamun, Soranus, and Ps. Apuleius. This work presents interesting linguistic features, including otherwise unattested Greek and Latin technical terms and unique pharmacological descriptions. Nicholas Everett provides a window onto the medieval translation of ancient science and medieval conceptions of pharmacy. With a comprehensive scholarly apparatus and a contextual introduction, The Alphabet of Galen is a major resource for understanding the richness and diversity of medical history.
  • 2013 Wiley
    edited by János Fischer, C. Robin Ganellin, David P. Rotella.
    General Aspects. Pioneer and Analogue Drugs / Janos Fischer, C Robin Ganellin, David P Rotella -- Competition in the Pharmaceutical Drug Development / Christian Tyrchan, Fabrizio Giordanetto -- Metabolic Stability and Analogue-Based Drug Discovery / Amit S Kalgutkar, Antonia F Stepan -- Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / A Ganesan -- Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Joseph A Jakubowski, Atsuhiro Sugidachi -- Selective Estrogen Receptor Modulators / Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / Kazumi Kondo, Hidenori Ogawa -- The Development of Cysteinyl Leukotriene Receptor Antagonists / Peter R Bernstein -- Case Studies. The Discovery of Dabigatran Etexilate / Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- The Discovery of Citalopram and Its Refinement to Escitalopram / Klaus P Bogeso, Connie Sanchez -- Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Helmut Buschmann -- Novel Taxanes: Cabazitaxel Case Study / Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- A New-Generation Uric Acid Production Inhibitor: Febuxostat / Ken Okamoto, Shiro Kondo, Takeshi Nishino.
  • 2012 Wiley
    edited by Hanns-Christian Mahler, Wim Jiskoot.
    The critical need for robust assays for quantitation and characterization of aggregates of therapeutic proteins -- Separation based analytical methods for measuring protein aggregation -- Laser light scattering-based techniques used for the characterization of protein therapeutics -- Online detection methods and emerging techniques for soluble aggregates in protein pharmaceuticals -- Analytical methods to measure sub-visible particulates -- Detection of visible particles in parenteral products -- Characterization of aggregates and particles using emerging techniques -- Ultraviolet absorption spectroscopy -- Fluorescence spectroscopy to characterize protein aggregates and particles -- Infrared spectroscopy to characterize protein aggregates -- Raman microscopy for characterization of particles -- Microscopic methods for particle characterization in protein pharmaceuticals -- Comparison of methods for soluble aggregate detection and size characterization -- Protein purification and its relation to protein aggregation and particles -- Formulation development and its relation to protein aggregation and particles.
  • 2013 Springer
    Shaker A. Mousa, Paul J. Davis, editors.
    This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
  • ebrary
    Jason C. Gallagher, Conan MacDougall ; senior acquisitions editor, Katey Birtcher ; cover design, Michael O'Donnell.
    Part 1. Considerations with antibiotic therapy -- Part 2. Antibacterial drugs -- Part 3. Antimycobacterial drugs -- Part 4. Antifungal drugs -- Part 5. Antiviral drugs -- Part 6. Antiparasitic Drugs -- Appendix 1. Selected normal human flora -- Appendix 2. Spectrum of activity -- Appendix 3. Empiric regimens for common infections -- Index.
  • 2014 Springer
    Tomás G. Villa, Patricia Veiga-Crespo, editors.
    Since penicillin and salvarsan were discovered, a number of new drugs to combat infectious diseases have been developed, but at the same time, the number of multi-resistant microorganism strains is increasing. Thus, the design of new and effective antibacterial, antiviral and antifungal agents will be a major challenge in the next years. This book reviews the current state-of-the-art in antimicrobial research and discusses new strategies for the design and discovery of novel therapies. Topics covered include the use of genetic engineering, genome mining, manipulation of gene clusters, X-ray and neutron scattering as well as the antimicrobial effects of essential oils, antimicrobial agents of plant origin, beta-lactam antibiotics, antimicrobial peptides, and cell-wall-affecting antifungal antibiotics.
  • 2015 Wiley
    Daniel Lednicer.
    "Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"-- Provided by publisher.
  • 2013 CRCnetBASE
    Robert S. Matson.
    Omics & microarrays revisited -- The commercial microarrays -- Supports & surface chemistries -- The arraying processes -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays.
  • 2012
    Ben Goldacre.
  • 2006
    James E. De Muth.
    Status: Not Checked OutLane Catalog Record
  • 2007 CRCnetBASE
    edited by Ramesh N. Patel.
    ch. 1. Nitrilases and nitrile hydratases / Robert DiCosimo -- ch. 2. Biocatalytic deracemization : dynamic resolution, stereoinversion, enantioconvergent processes, and cyclic deracemization / Yolanda Simeo, Wolfgang Kroutil, and Kurt Faber -- ch. 3. A decade of biocatalysis at Glaxo Wellcome / Mahmoud Mahmoudian -- ch. 4. Biocatalysis for synthesis for chiral pharamaceutical intermediates / Ramesh N. Patel -- ch. 5. Directed evolution of lipases and esterases for organic synthesis / Aurelio Hidalgo and Uwe T. Bornscheuer -- ch. 6. Flavin-containing oxidative biocatalysts / Marco W. Fraaije and Willem J.H. van Berkel -- ch. 7. Preparation of chiral pharmaceuticals through enzymatic acylation of alcohols and amines / Vicente Gotor-Fernandez, Francisca Rebolledo, and Vicente Gotor -- ch. 8. Dynamic kinetic resolution and asymmetric transformations by enzyme-metal combinations / Mahn-Joo Kim, Yangsoo Ahn, and Jaiwook Park -- ch. 9. Biotransformation of natural or synthetic compounds for the generation of molecular diversity / Robert Azerad -- ch. 10. Applications of aromatic hydrocarbon dioxygenases / Rebecca E. Parales and Sol M. Resnick -- ch. 11. A genomic approach to investigating baker's yeast reductions / Jon D. Stewart -- ch. 12. Immobilization of enzymes as cross-linked enzyme aggregates : a simple method for improving performance / Roger A. Sheldon -- ch. 13. Biotechnological applications of aldolases / Wolf-Dieter Fessner and Stefan Jennewein -- ch. 14. Enzymatic synthesis of modified nucleosides / Luis A. Condezo ... [et al.] -- ch. 15. Biocatalytic reduction of carbozylic acids : mechanism and applications / Padmesh Venkitasubramanian, Lacy Daniels, and John P.N. Rosazza -- ch. 16. Dehalogenases in biodegradation and biocatalysis / Dick B. Janssen -- ch. 17. Enzymatic synthesis of sugar esters and oligosaccharides from renewable resources / A. Ballestros ... [et al.] -- ch. 18. Efficient methods and instrumentation for engineering custom enzymes / Steven J. Robles, William J. Coleman, and Mary M. Yang -- ch. 19. Deaminating enzymes of the purine cycle as biocatalysts for chemoezymatic synthesis and transformation of antiviral agents structurally related to purine nucleosides / Enzo Santaniello, Pierangela Ciuffreda, and Laura Alessandrini -- ch. 20. Mircobial and enzymatic processes for the production of chiral compounds / Kohsuke Honda ... [et al.] -- ch. 21. Discovery of arylmalonate decarbozylase and conversion of the function by rational design / Kenji Miyamoto and Hiromichi Ohta -- ch. 22. Chemoenzymatic preparation of enantiopure building blocks of synthetic utility / Kenji Mori -- ch. 23. Stereoselective modifications of polyhydorxylated steroids / Elena Fossati and Sergio Riva -- ch. 24. Recent developments in enzymatic acyloin condensations / Owen Ward and Ajay Singh -- ch. 25. Synthesis of chiral alcohols with carbonyl reductase library and robust NAD(P)H regenerating system / Hiroaki Yamamoto and Akinobu Matsuyama -- ch. 26. Comparative analysis of chemical and biocatalyic syntheses of drug intermediates / Michael J. Homann ... [et al.] -- ch. 27. Industrial processes using lyases fo C-C, C-N, and C-O bond formation / Martina Pohl an Andreas Lieses -- ch. 28. State of the art and applications in stereoselective synthesis of chiral cyanohydrins / Franz Effenberger, Siegfried Forster, and Christoph Kobler -- ch. 29. Chiral switches : problems, strategies, opportunities, and experiences / Rene Csuk -- ch. 30. Enzyme evolution for chemical process applications / Gjalt W. Huisman and James J. Lalonde -- ch. 31. Biocatalytic routes to nonracemic chiral amines / Nicholas J. Turner and Reuban Carr -- ch. 32. Enantioselective biocatalytic reduction of ketones for the synthesis of optically active alcohols / Stefan Buchholz and Harald Groger -- ch. 33. Enyzmes catalysis in nonaqueous media : past, present and future / Susanne Dreyer ... [et al.] -- ch. 34. Biocatalyic concepts for the synthesis of optically active amines / Stefan Buchholz and Harald Groger.
  • 2007 CRCnetBASE
    edited by Andrew Carmen, Gary Hardiman.
  • 2013 Wiley
    Rodney J.Y. Ho, Milo Gibaldi.
    Introduction to biopharmaceuticals -- Distinctions of biologic versus small molecule platforms in drug development -- Financing biologic drug development -- Application of biotechnology in drug discovery and early development -- Large-scale production of recombinant proteins -- Clinical pharmacology, toxicology, and therapeutic dosage & response -- Clinical evaluation and regulatory approval & enforcement of biopharmaceuticals -- Pharmacoeconomics and drug pricing / Garrison -- Antibodies and derivatives -- Hematopoietic growth and coagulation factors -- Cytokines and interferons -- Hormones -- Enzymes -- Vaccines / Hu, Ho -- Other biopharmaceutical products -- Advances in personalized medicine : pharmacogenetics in drug therapy -- Gene and cell therapy -- Pharmacoeconomics, outcome, and health technology assessment research in drug development -- Summary and future prospects.
  • 2010 Wiley
    Abraham, Donald J.; Burger, Alfred; Rotella, David P.
    "... provides an established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development. This flagship reference for medicinal chemists and pharmaceutical professions has been thoroughly updated and expanded across 8 volumes to incorporate the entire process of drug development (preclinical testing, clinical trials, etc.) alongside the traditional strengths in medicinal chemistry and drug discovery"--Provided by publisher.
  • 2008 ebrary
    Martin Austin.
    The role of business development -- Planning the portfolio -- Identifying the needs -- Profiling and searching for opportunities -- Modelling and valuation -- Structuring for value -- Due diligence and negotiations -- Sealing the deal : the control -- Making the transaction work.
  • 2013 Springer
    You Han Bae, Randall J. Mrsny, Kinam Park, editors.
    A Time Travel Journey Through Cancer Therapies -- Nanotechnology for Cancer Treatment: Possibilities & Limitations -- Vascular Targeting Approaches to Treat Cancer -- Tumor Immunotherapy by Utilizing a Double-Edged Sword Chemokines -- Cancer Biology: Some Causes for a Variety of Different Diseases -- Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on Nature of Tumor Stroma -- Cancer Cell Respiration: Hypoxia and pH in Solid Tumors -- Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots -- Pressure Gradients in Solid Tumors -- The ADAMs: New Therapeutic Targets for Cancer? -- Role of the Extracellular Matrix Enzyme Activities and Metastasis -- The Role of Non-Cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis -- Heterogeneity of Cancers and its Implication for Targeted Drug Delivery -- A Study of Cancer Heterogeneity: From Genetic Instability to Epigenetic Diversity in Colorectal Cancer -- Nanotherapeutics in Multidrug Resistance -- Stem Cells and Cancer -- Mechanisms of Metastasis -- Cancer-Specific Ligand/Receptor Interactions -- Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell -- Long Circulation and Tumor Accumulation -- Convective and Diffusive Transport in Drug Delivery -- Intravital Real-Time Confocal Laser Scanning Microscopy for the in Situ Evaluation of Nanocarriers -- The EPR effect in Cancer Therapy -- In Vitro 3-dimensional Cancer Culture Model -- Complex Transport Around Tumor: Need for Realistic In Vitro Tumor Transport Model -- The Missing Components Today and the New Treatments Tomorrow.
  • 2014 Springer
    Karen Sliwa, John Anthony, editors.
    In the western world, the risk of cardiovascular disease in pregnancy has grown due to the increasing age at the first pregnancy and the worldwide obesity epidemic leading to early diabetes and hypertension. As a result more women are requiring drug therapy during pregnancy and some data has shown an altered pharmacodynamic profile in pregnant women when compared to the non-pregnant population. Cardiac Drugs in Pregnancy presents up-to-date research for the treatment of cardiovascular disease during pregnancy, and discusses the most important indications of drug usage in pregnancy and postpartum. The book aims to assess the potential risk of drugs and their possible benefit against each other, making it an essential read for a wide range of health professionals involved in cardiac drug therapy in pregnancy.
  • 2015 Springer
    [edited by] Catherine Marcucci, Michael P. Hutchens, Erica D. Wittwer, Toby N. Weingarten, Juraj Sprung, Wayne T. Nicholson, Kirk Lalwani, David G. Metro, Randal O. Dull, Christopher E. Swide, F. Jacob Seagull, Jeffrey R. Kirsch, Neil B. Sandson.
  • 2005 CRCnetBASE
    edited by Sadettin S. Ozturk, Wei-Shou Hu.
  • 2013 Springer
    John Geigert.
    An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).
  • 2007 NAP
    Leslie Pray and Sally Robinson, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
  • 2005 Springer
    G. Festel ... [et al.].
  • 2013 Wiley
    edited by Pedro Merino.
    Deoxynucleoside analogues / Vicente Gotor -- Nucleosides modified at the base moiety / Luigi Agrofoglio -- Acyclic nucleosides / Antonin Holy -- Phosphorylated nucleoside analogues / Giovanni Romeo -- Triphosphorylated nucleoside analogues / Chris Meier -- Pro-nucleotides / Christian Perigaud -- C-nucleoside / Sergio Castillón -- Isonucleosides / Vasu Nair -- Conformationally constrained nucleosides / Jacques Lebreton -- Spironucleosides / Maria Jose Camarasa -- L-nucleosides / Daniela Perrone -- Carbocyclic nucleosides / Eric Leclerc -- Uncommon three-, four, and six-membered nucleosides / Elisabetta Groaz -- Thionucleosides / L.S. Jeong -- Azanucleosides and related compounds / Tomas Tejero -- Oxathiolane and dioxolane nucleosides / Annalisa Guaragna -- Isoxazolidinyl nucleosides / Ugo Chiacchio -- Nucleoside antibiotics / Apurba Dutta -- Building blocks for peptide nucleic acids / Pedro Merino.
  • 2008 CRCnetBASE
    [edited by] E.A. Rekka, P.N. Kourounakis.
    Inflammatory mechanisms in Alzheimer's disease and other neurodegenerative disorders / Joseph Rogers ... [et al.] -- Treatment development strategies for Alzheimer's disease / Ernst Wulfert -- Lipoprotein-associated phospholipase A as a new prognostic factor for coronary artery disease / Alexandros D. Tselepis -- New molecular targets for the prevention and treatment of gastrointestinal ulcers and inflammation / Sandor Szabo ... [et al.] -- Stress activates corticotropin releasing : factor signaling pathways : implication in functional bowel disorders / Yvette Tache -- Design, synthesis, and pharmacological evaluation of high-affinity and selectivity sigma-1 and sigma-2 receptor ligands / Jacques H. Poupaert -- Synthesis of biologically active taxoids / K.C. Nicolaou and R.K. Guy -- From the molecular pharmacology to the medicinal chemistry of cannabinoids / Didier M. Lambert -- An appraisal of fomocaines : current situation and outlook / Herbert Oelschlager and Andreas Seeling -- Ligands for the GABA recognition site at the GABAA receptor : structure-activity studies / Bente Frlund ... [et al.] -- Strategies for development of new lead structures for inhibition of acetylcholinesterase / Petra Kapkova ... [et al.] -- Discovery of potent and selective inhibitors of human aldosterone synthase (CYP11B2) : a new target for the treatment of congestive heart failure and myocardial fibrosis--a review / R.W. Hartmann ... [et al.] -- Thiocarboxanilides : a new class of nonnucleoside reverse transcriptase inhibitors (NNRTIs) with great potential for the treatment of human immunodeficiency virus type 1 (HIV-1) infections / E. De Clercq, A. Karlsson, and J. Balzarini -- Histamine H-receptor agonists and antagonists : chemical, pharmacological, and clinical aspects / Holger Stark and Walter Schunack -- Anti-inflammatory actions of flavonoids and structural requirements for new design / Theoharis C. Theoharides -- Molecular mechanisms of HO-induced DNA damage : the action of desferrioxamine / M. Tenopoulou, P.-T Doulias, and D. Galaris -- LNA (locked nucleic acid) and functionalized LNA : towards efficient gene targeting / Jesper Wengel -- The effect of diet on drug metabolism / K.J. Netter -- Cytochromes P450 in the metabolism and bioactivation of chemicals / Costas Ioannides -- In vitro methods to measure drug metabolism and drug interactions in drug discovery and development / O. Pelkonen ... [et al.] -- How to probe the sites of action of drug molecules / A. Makriyannis and F. Bitter -- Physicochemical profiling in early drug discovery : new challenges at the age of high-throughput screen and combinatorial chemistry / Bernard Faller -- Drug membrane interaction and its importance for drug efficacy / J.K. Seydel ... [et al.] -- The fight against AIDS : new avenues for inhibiting reverse transcriptase (RT), and old target / Maurizio Botta ... [et al.].
  • 2013 Springer Protocols
    edited by Gerhard K.E. Scriba.
    Chiral recognition in separation science : an overview / Gerhard K.E. Scriba -- Enantioseparations by thin-layer chromatography / Massimo Del Bubba [and others] -- Gas-chromatographic enantioseparation of unfunctionalized chiral hydrocarbons : an overview / Volker Schurig and Diana Krieidler -- HPLC enantioseparation on cyclodextrin-based chiral stationary phases / Yong Wang and Siu Choon Ng -- Enantioseparations by high-performance liquid chromatography using polysaccharide-based chiral stationary phases : an overview / Bezhan Chankvetadze -- Common screening approaches for efficient analytical method development in LC and SFC on columns packed with immobilized polysaccharide-derived chiral stationary phases / Pilar Franco and Tong Zhang -- Chiral separations by HPLC on immobilized polysaccharide chiral stationary phases / Imran Ali, Zeid A. AL-Othman, and Hassan Y. Aboul-Enein -- Enantioseparations by high-performance liquid chromatography using macrocyclic glycopeptide-based chiral stationary phases : an overview / István Ilisz [and others] -- Enantioseparations of primary amino compounds by high-performance liquid chromatography using chiral crown ether-based chiral stationary phase / Myung Ho Hyun -- Screening of Pirkle-type chiral stationary phases for HPLC enantioseparations / Gregory K. Webster and Ted J. Szczerba -- Enantioseparations by high-performance liquid chromatography based on chiral ligand-exchange / Benedetto Natalini, Roccaldo Sardella, and Federica Ianni -- Enantioseparations by high-performance liquid chromatography using molecularly imprinted polymers / David A. Spivak -- Chiral mobile phase additives in HPLC enantioseparations / Lushan Yu, Shengjia Wang, and Su Zeng -- Chiral benzofurazan-derived derivatization reagents for indirect enantioseparations by HPLC / Toshimasa Toyo'oka -- Separation of racemic 1-(9-Anthryl)-2,2,2-trifluoroethanol by sub-/supercritical fluid chromatography / Xiqin Yang, Leo Hsu, and Gerald Terfloth -- Chiral separations by simulated moving bed method using polysaccharide-based chiral stationary phases / Toshiharu Minoda -- Enantioseparations by capillary electrophoresis using cyclodextrins as chiral selectors / Gerhard K.E. Scriba and Pavel Jáč -- Application of dual cyclodextrin systems in capillary electrophoresis enantioseparations / Anne-Catherine Servais and Marianne Fillet -- Enantioseparations in nonaqueous capillary electrophoresis using charged cyclodextrins / Anne-Catherine Servais and Marianne Fillet -- Use of macrocyclic antibiotics as the chiral selectors in capillary electrophoresis / Chengke Li and Jingwu Kang -- Application of polymeric surfactants in chiral micellar electrokinetic chromatography (CMEKC) and CMEKC coupled to mass spectrometry / Jun He and Shahab A. Shamsi -- Cyclodextrin-modified micellar electrokinetic chromatography for enantioseparations / Wan Aini Wan Ibrahim, Dadan Hermawan, and Mohd Marsin Sanagi -- Cyclodextrin-mediated enantioseparation in microemulsion electrokinetic chromatography / Claudia Borst and Ulrike Holzgrabe -- Chiral separations by capillary electrophoresis using proteins as chiral selectors / Jun Haginaka -- Enantioseparation by chiral ligand-exchange capillary electrophoresis / Yi Chen and Lijuan Song -- Experimental design methodologies in the optimization of chiral CE or CEC separations : an overview / Bieke Dejaegher, Debby Mangelings, and Yvan Vander Heyden -- Chiral capillary electrophoresis-mass spectrometry / Elena Domínguez-Vega, Antonio L. Crego, and Maria Luisa Marina -- Application of chiral ligand-exchange stationary phases in capillary electrochromatography / Martin G. Schmid -- Polysaccharide-derived chiral stationary phases in capillary electrochromatography enantioseparations / Zhenbin Zhang, Hanfa Zou, and Junjie Ou -- Open tubular molecular imprinted phases in chiral capillary electrochromatography / Won Jo Cheong and Song Hee Yang -- Enantioseparations in capillary electrochromatography using sulfated poly [beta]-cyclodextrin-modified silica-based monolith as stationary phase / Ruijuan Yuan and Guosheng Ding -- Cyclodextrin-mediated enantioseparations by capillary electrochromatography / Dorothee Wistuba and Volker Schurig.
  • 2014 CRCnetBASE
    editor, Se-Kwon Kim.
    Part 1. Synthesis and characterization of chitin and chitosan derivatives -- part 2. Biological activities of chitin and chitosan derivatives -- part 3. Biomedical applications of chitin and chitosan derivatives.
  • 2012 ScienceDirect
    Karen J. Tietze.
    Introduction : the practice of clinical pharmacy -- Communication skills for the pharmacist -- Taking medication histories -- Physical assessment skills -- Review of laboratory and diagnostic tests -- The patient case presentation -- Therapeutics planning -- Monitoring drug therapies -- Researching and providing drug information -- Ethics in pharmacy and health care.
  • 2006 CRCnetBASE
    [edited by] Chi-Jen Lee ... [et al.].
  • 2015 Wiley
    Laurent Simon and Juan Ospina.
    "Covers the modeling of drug-delivery systems and provides mathematical tools to evaluate and build controlled-release devices"--Provided by publisher.
  • 2008 CRCnetBASE
    Smita Gopalaswamy, Venky Gopalaswamy.
    Overview of combination products -- Ensuring successful combination product development -- Overview of FDA and other regulatory agency expectations -- Resource requirements -- Manufacturing of combination products -- Challenges and pitfalls to avoid with combination products -- Postlaunch compliance requirements -- Agency audits and challenges.
  • 2013 ClinicalKey
    Paul Rutter.
    Respiratory system -- Ophthalmology -- Ear conditions -- Central nervous system -- Women's health -- Gastroenterology -- Dermatology -- Musculoskeletal conditions -- Paediatrics -- Specific product requests.
  • 2011 Springer
    Shayne C. Gad, Charles B. Spainhour.
  • 2013 Wiley
    Laurent Simon.
    Mathematical models -- Linearization and deviation variables -- Stability considerations -- Laplace transforms of linear systems -- Inverse laplace transforms -- Transfer functions -- Dynamic behaviors of typical plants -- Closed-loop responses with P, PI and PID controllers -- Frequency response analysis -- Stability analysis of feedback systems -- Design of feedback controllers -- Feedback control of dead-time systems -- Cascade and feedforward control strategies -- Effective time constant -- Optimal control and design.
  • 2011 Springer
    Clive G. Wilson, Patrick J. Crowley, editors.
    A short history of controlled drug release -- The organization of the gut and oral absorption of drugs: anatomical, biological and physiological considerations in oral formulation development -- Controlling drug release in oral product development programs: an industrial perspective -- Animal model systems suitable for controlled release modeling -- In Vitro testing of controlled release dosage forms during development and manufacture -- Oral controlled delivery mechanisms and technologies -- Drug-polymer matrices for extended release -- Ion-exchange approaches to controlling drug release -- Pulsatile delivery for controlling drug release -- Ordered mesoporous silica for the delivery of poorly soluble drugs -- Geometric release systems: principles, release mechanisms, kinetics, polymer science, and release-modifying material -- Extrudable technologies for controlling drug release -- Coated multiparticles for controlling drug release -- Capsules as a delivery system for modified-release products -- Lipids in oral controlled release drug delivery -- Biccal drug delivery -- Controlling release by gastroretention -- Drug delivery to the colon.
  • 2005 CRCnetBASE
    edited by Peter Elsner, Howard I. Maibach.
  • 2010 Springer
    edited by Steven J. Shire, Genentech, Inc., San Francisco, CA USA, Wayne Gombotz, Omeros Corporation, Seattle, WA USA, Karoline Bechtold-Peters, Boehringer Ingelheim Pharma, Biberach, Germany, James Andya, Genentech, Inc., San Francisco, CA USA.
    Introduction / Wayne R. Gombotz and Steven J. Shire -- Design of therapeutic MABS. CDR repair: a novel approach to antibody humanization / Mark S. Dennis -- Nanobodies, single-domain antigen-binding fragments of camelid heavy-chain antibodies / Gholamreza Hassanzadeh Ghassabeh, Serge Muyldermans, and Dirk Saerens -- Expression and production of MABS. GPEx® a flexible method for the rapid generation of stable, high expressing, antibody producing mammalian cells lines / Gregory T. Bleck -- Advancing our cell culture platform: incorporating lessons learned and new technologies / Carole Heath -- Recovery and purification. Addressing changes associated with technology transfer: a case study / Michele M. Myers ... [et al.] -- Concepts for disposables in biopharmaceutical manufacture / Joachim K. Walter and Uwe Gottschalk -- Formulation and delivery. Formulation and delivery issues for monoclonal antibody therapeutics / Ann L. Daugherty and Randall J. Mrsny -- Challenges in the development of high protein concentration formulations / Steven J. Shire, Zahra Shahrock, and Jun Liu -- Protein immobilization by crystallization and precipitation: an alternative to lyophilization / Karoline Bechtold-Peters -- Analytics and specification setting for MABS. Characterizing high affinity antigen/antibody complexes by kinetic and equilibrium based methods / Andrew W. Drake, David G. Myszka, and Scott L. Klakamp -- Analytical characterization of monoclonal antibodies: linking structure to function / Reed J. Harris ... [et al.] -- Analysis of irreversible aggregation, reversible self-association and fragmentation of monoclonal antibodies by analytical ultracentrifugation / James D. Andya, Jun Liu, and Steven J. Shires -- Biophysical signatures of monoconal antibodies / N. Harn ... [et al.] -- Pharmacokinetics and immunogenicity. Impact of Fc glycosylation on monoclonal antibody effector functions and degradation by proteases / T. Shantha Raju -- Immunogenicity assessment of antibody therapeutics / P. stas, Y. Gansemans, and I. Lasters -- Armed antibodies and new classes of antibodies. Production of monoclonal antibodies in E. coli / Dorothea E. Reilly and Daniel G. Yansura -- Recent advances in the use of antibody drug conjugates for cancer theapy / Peter D. Senter -- Antibody radiolabeling / Corinne Bensimon and Russell Redshaw.
  • 2010 Karger
    volume editors, J.F. Cryan, B.E. Leonard.
    Antidepressant compounds : a critical review / S.W. Tang, D.M. Helmeste, B. Leonard -- The hypothalamic-pituitary-adrenal axis in depression / M. Julio-Pieper, T.G. Dinan -- Dysfunctional circadian rhythms and mood disorders : opportunities for novel therapeutic approaches / T.R. Norman -- The concept of depression as a dysfunction of the immune system / B.E. Leonard -- The role of polyunsaturated fatty acids in the pathology and treatment of depression / C. Song -- Overcoming antidepressant treatment resistance : focus on glutamate / J.W. Murrough, S.J. Mathew -- Neuroimaging and the pathophysiology and treatment of depression : recent advances and future needs / D.M. Cannon -- Animal models of depression : where are we going? / D.A. Slattery, J.F. Cryan -- Genetic models of depression and antidepressant response / I. Lucki -- The role of 5-HT2C receptors in the antidepressant response : a critical review / C.B.P. Martin ... [et al.] -- Chromatin-based treatments for affective disorders : insight or utopia / H.E. Covington III, O. Berton -- Neurotrophic factors and antidepressant action : recent advances / O.F. O'Leary, E. Castron -- Neurogenic basis of antidepressant action : recent advances / A. Tanti, C. Belzung -- The nature and treatment of therapy-resistant depression / S.H. Kennedy, S.J. Rizvi, P. Giacobbe -- Optimizing antidepressant management of depression : current status and future perspectives / T.L. Schwartz, S.M. Stahl.
  • 2009 ScienceDirect
    executive editors, Yihong Qiu, Yisheng Chen, Geoff G.Z. Zhang ; associate editors, Lirong Liu, William R. Porter.
  • 2013 Springer
    Gerhard Nahler with contribution by Annette Mollet.
    This dictionary details various terms typically used in pharmaceutical medicine. It also explains commonly used abbreviations.
  • 2005 CRCnetBASE
    Stefania Spada and Gary Walsh.
  • 2015 Springer
    Allen C. Templeton, Stephen R. Byrn, Roy J. Haskell, Thomas E. Prisinzano, editors.
    This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.
  • 2014 NAP
    Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy.
    "Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements, and Activities is part of a study of how data from clinical trials might best be shared. This document is designed as a framework for discussion and public comment. This framework is being released to stimulate reactions and comments from stakeholders and the public. The framework summarizes the committee's initial thoughts on guiding principles that underpin responsible sharing of clinical trial data, defines key elements of clinical trial data and data sharing, and describes a selected set of clinical trial data sharing activities."--Publisher's website.
  • 2006 Springer
    Naitee Ting, editor.
  • 2006 CRCnetBASE
    edited by Rajesh Krishna.
  • 2014 Wiley
    edited by Chun Li, Mei Tian.
    Introduction to molecular imaging / Vikas Kundra -- PET/SPECT : instrumentation and imaging techniques / Yuan-Chuan Tai -- Photoacoustic tomography and its application in drug delivery and photothermal therapy / Liang Song Lihong Wang -- Raman microspectral imaging for label-free detection of nanoparticle-mediated cellular and sub-cellular drug delivery / Tatyana Chernenko ... [et al.] -- Anatomical and functional MRIi / Edward F. Jackson -- Quantitative imaging in drug delivery / Kooresh Shoghi -- PET imaging of small-molecular-weight drug pharmacokinetics / Stephen M. Moerlein and Zhude Tu -- Imaging peptides, proteins, and antibody delivery / F. L. Giesel and C. Kratochwil -- In vivo imaging and delivery of siRNA / Zdravka Medarova and Anna Moore -- Imaging cell therapy / Yijie Linag and Jeff W.M. Bulte -- Radiolabeled liposomes as drug delivery nano-theranostics / William T. Phillips ... [et al.] -- Polymeric micelles as imaging agents and drug delivery systems / Jun Zhao and Chun Li -- Perfluorocarbon nanoparticles: translating bench opportunities to the clinic / G.M. Lanza ... [et al.] -- Cancer theranostics with hollow gold nanospheres / Wei Lu and Chun Li -- Imaging pulmonary drug delivery / Stephen Newman -- In-vivo imaging for validation of oral dose performance / Fiona McInnes and Howard Stevens -- Role of large animal models in translational studies of imaging and targeted drug delivery / Rajesh K. Uthamanthil and Mei Tian -- Imaging transcatheter delivery to liver tumors / Adil AL-Nahhas, Meeran Naji, Imene Zerizer -- Direct visualization of therapeutic radionuclides distribution using nuclear medicine imaging: i-131 in metastatic thyroid carcinoma / Ho Young Lee ... [et al.] -- Imaging drug delivery to the cns using translational positron emission tomography studies / Chi-Ming Lee, Katarina Varns.
  • 2013 Wiley
    edited by Dennis Douroumis and Alfred Fahr.
    Self-assembled delivery vehicles for poorly water-soluble drugs : basic theoretical considerations and modeling concepts / Silvio May and Alfred Fahr -- Liposome as intravenous solubilizers for poorly water soluble drugs / Peter van Hoogevest, Mathew Leigh and Alfred Fahr -- Drug solubilization and stabilization of cyclodextrin drug carriers / Thorsteinn Loftsson and Marcus Eli Brewster -- Solid lipid nanoparticles for drug delivery / Sonja Joseph and Heike Bunjes -- Polymeric drug delivery systems for encapsulating hydrophobic drugs / Naveed Ahmed, C.E. Mora-Heurtas, Chiraz Jaafar-Maalej, Hatem Fessi and Abdelhamid Elaissari -- Polymeric drug delivery systems for encapsulating hydrophobic drugs / Dagmar Fischer -- Development of self-emulsifying drug delivery systems (SEDDS) for oral ioavailability enhancement of poorly soluble drugs / Dimitrios G. Fatouros and Anette Müllertz -- Novel top-down technologies : effective production of ultra-fine drug nanocrystals / Cornelia. M. Keck, S. Kobierski, R. Mauludin and Rainer H. Müller -- Nanosuspensions with enhanced drug dissolution rates of poorly water-soluble drugs / Dennis Douroumis -- Microemulsions for drug solubilization and delivery / X.Q. Wang and Qiang Zhang -- Enhancing drug solubility and bioavailability using hot melt extruded solid dispersions / Shu Li, David S. Jones and Gavin P. Andrews -- Penetration enhancers, solvents and the skin / Jonathan Hadgraft and Majella E. Lane -- Dendrimers for enhanced drug solubilization / Narendra K. Jain and Rakesh K. Tekade -- Polymeric micelles for the delivery of poorly soluble drugs / Swati Biswas, Onkar S. Vaze, Sara Movassaghian and Vladimir P. Torchilin -- Nanostructured silicon-based materials as a drug delivery system for water insoluble drugs / Vesa-Pekka Lehto, Jarno Salonen, Helder Santos and Joakim Riikonen -- Micro- and nanosizing of poorly soluble drugs by grinding techniques / Stefan Scheler -- Enhanced solubility of poorly soluble drugs via spray drying / Cordin Arpagaus, David Rütti and Marco Meuri.
  • 2014 Springer
    Margareta Hammarlund-Udenaes, Elizabeth C.M. de Lange, Robert G. Thorne, editors.
    This book describes the different approaches for drug delivery to the brain with an emphasis on the physiology of the blood-brain barrier (BBB) and the governing principles and concepts for drug delivery across the BBB. It contains cutting-edge methods for studying drug delivery and administering drugs into the brain. The book also explores different approaches for predicting human brain concentrations as well as the influence of disease and drug industry perspectives. In addition to wide-ranging coverage of physiological concepts relevant to central nervous system (CNS) drug delivery, a detailed review of brain structure, function, blood supply and fluids is also provided. In each chapter, descriptions of future challenges and unresolved questions are combined with points for discussion. This unique combination of material makes this book a valuable resource for students and for established academic and industry scientists looking to learn about state-of-the-art drug delivery research. It is also a source for stimulating new ideas among experts already performing CNS drug delivery research or working in related areas. Margareta Hammarlund-Udenaes (Ph.D.) is a Professor in Pharmacokinetics and Pharmacodynamics (PK/PD) at Uppsala University and the Head of the Translational PK/PD Group. Her research is focused on studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, and it has led to the development of new concepts and methods within the BBB transport area, focusing on unbound drug relationships. Elizabeth C.M. de Lange (Ph.D.) is Head of the Target Site Equilibration Group at the Division of Pharmacology of the Leiden Academic Center for Drug Research (LACDR). Her research program focuses on the development of generally applicable predictive PK/PD models on CNS drugs using advanced in vivo animal models and mathematical modeling techniques, with a number of recent successes. Robert G. Thorne (Ph.D.) is an Assistant Professor in Pharmaceutical Sciences at the University of Wisconsin-Madison School of Pharmacy. He was previously a research scientist and faculty member in the Department of Physiology & Neuroscience at the New York University School of Medicine. His research focuses on diffusive and convective transport within the CNS and the development, refinement and optimization of strategies for delivering biologics into the brain.
  • 2005 CRCnetBASE
    [editors] Tapash K. Ghosh, William R. Pfister.
  • 2013 Springer
    Gerhard Klebe.
    Unique work on structure-based drug design, covering multiple aspects of drug discovery and development. Fully colored, many images, computer animations of 3D structures (these only in electronic form). Makes the spatial aspects of interacting molecules clear to the reader, covers multiple applications and methods in drug design. Structures by mode of action, no therapeutic areas. Of high relevance for academia and industrial research. Focus on gene technology in drug design, omics-technologies computational methods experimental techniques of structure determinationmultiple examples on mode of action of current drugs, ADME-tox properties in drug development, QSAR methods, combinatorial chemistry, biologicals, ribosome, targeting protein-protein interfaces.
  • 2005 Wiley
    edited by Shayne Cox Gad.
    Introduction. Drug discovery in the 21st century -- ch. 1. Natural products / Charles B. Spainhour -- ch. 2. Cancer cell proteomics using molecular aptamers / Weihong Tan ... [et al.] -- ch. 3. Molecular similarity methods and QSAR models as tools for virtual screening / Jürgen Bajorath -- ch. 4. Systems biology : applications in drug discovery / Sean Ekins ...[et al.] -- ch. 5. High throughput flow cytometry / Larry A. Sklar ... [et al.] -- ch. 6. Combining NMR spectral information with associated structural features to form computationally nonintensive, rugged, and objective models of biological activity / Richard D. Beger, Dan A. Buzatu, and Jon G. Wilkes -- ch. 7. Using Microsoft Excel as a laboratory data management tool / A. Erik Rubin, Mark F. Russo, and William Neil -- ch. 8. Age of regulation / Sandy Weinberg and Gerald J. Whartenby -- ch. 9. Simultaneous screening of multiple cell lines using the CellCard system / Oren E. Beske -- ch. 10. Protein X-ray crystallography in drug discovery / Peter Nollert ... [et al.] -- ch. 11. Biological and chemistry assays available during drug discovery and developability assessment / Duane B. Lakings -- ch. 12. Strategies and methods in monitoring and targeting protein-protein interactions / Arianna Loregian and Giorgio Palù -- ch. 13. High-throughput screening : evolution of technology and methods -- Martyn N. Banks ... [et al.] -- ch. 14. Metal-enhanced fluorescence : application to high-throughput screening and drug discovery / Kadir Aslan ... [et al.] -- ch. 15. Methods for the design and analysis of replicate-experiment studies to establish assay reproducibility and the equivalence of two potency assays / Brian J. Eastwood ... [et al.] -- ch. 16. Coupled luminescent methods in drug discovery : 3-minute assays for cytotoxicity and phosphatase activity / Michael J. Corey and Robert J. Kinders -- ch. 17. Design and pharmaceutical applications of prodrugs / Tomi Järvinen ... [et al.] -- ch. 18. GABA and glutamate receptor ligands and their therapeutic potential in CNS disorders / Ulf Madsen ... [et al.] -- ch. 19. Cardiac sarcolemmal ATP-sensitive potassium channel antagonists : novel ischemia-selective antiarrhythmic agents / George E. Billman -- ch. 20. Factors influencing the efficacy of mediator-specific anti-inflammatory, glucocorticoid, and anticoagulant therapies for sepsis / Peter C. Minneci ... [et al.] -- ch. 21. Combinatorial chemistry in the drug discovery process / Nathan T. Ross, Brian R. McNaughton, and Benjamin L. Miller -- ch. 22. Herbal medicines and animal models of gastrointestinal diseases / C.H. Cho and J.K.S. Ko -- ch. 23. Endocrine and metabolic agents / Brian L. Furman -- ch. 24. Respiratory viruses / Paul D. Olivo -- ch. 25. Strategies in the design of antiviral drugs / Erik De Clercq and Piet Herdewijn -- ch. 26. Protein kinase inhibitors in drug discovery / Keykavous Parang and Gongqin Sun -- ch. 27. RNA-based therapies / Steve Pascolo -- ch. 28. Novel imaging agents for molecular MR imaging of cancer / Dmitri Artemov and Zaver M. Bhujwalla -- ch. 29. Targets and approaches for cancer drug discovery / Susan L. Mooberry.
  • 2011 Springer
    Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai, editors.
    Introduction to Drug-Drug Interactions -- Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion -- Mechanisms of Drug Interactions II: Transport Proteins -- Drug-Food Interactions -- Interactions Between Herbs and Antiinfective Medications -- Drug-Cytokine Interactions -- Beta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions with Antiretrovirals for HIV Infection -- Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelmintic Agents -- Drug Interaction Considerations Throughout Drug Development -- Probe Cocktail Studies -- Design and Data Analysis in Drug Interaction Studies.
  • 2011 Springer
    by Siamak Cyrus Khojasteh, Harvey Wong, Cornelis E.C.A. Hop.
    1. Pharmacokinetics -- 2. Drug Metabolizing Enzymes -- 3. Oral Absorption -- 4. Transporters -- 5. Metabolism-Based Drug Interactions -- 6. Biotransformation and Bioactivation -- 7. Prediction of Human Pharmacokinetics -- 8. Advances in Bioanalysis as It Relates to ADME -- 9. ADME Properties and Their Dependence on Physicochemical Properties -- 10. In Silico ADME Tools -- 11. Approved Drugs -- 12. Chemical Nomenclature.
  • 2006 CRCnetBASE
    edited by Donald C. Monkhouse, Charles F. Carney, James L. Clark.
  • 2015 Ovid
    Gerald G. Briggs, Roger K. Freeman.
  • 2007 ClinicalKey
    Lyn Weiss, Julie K. Silver, Ted A. Lennard and Jay M. Weiss
    Introduction to injections -- Medications and injection supplies -- Joints -- Tendons -- Bursae -- Nerves -- Trigger point injections -- Botulinum toxin -- Prolotherapy -- Acupuncture -- Sympathetic injections -- Spinal injections.
  • 2012 CRCnetBASE
    Alexander Scarlat ; foreword by John Halamka.
    "This book introduces readers to structured systems analysis and the medications domains. It starts off with top-down decomposition of workflows and data. It applies structured systems analysis methodology and tools to electronic prescription, computerized physician order entry, drug dispensation, medication administration, and clinical decision support. Providing a comprehensive view of the EHR/EMR, the text covers user interface considerations, reporting requirements, and standards and vocabularies for meaningful use. Assuming no previous clinical and/or informatics knowledge, the author uses accessible language and includes over 250 figures and 100 review questions with answers"--Provided by publisher.
  • 2007 ClinicalKey
    Mark Kester, Kelly D. Karpa, Kent E. Vrana.
    Pharmakokinetics -- Pharmacodynamics and signal transduction -- Toxicology -- Treatment of infectious diseases -- Cancer and immunopharmacology -- Autonomic nervous system -- Hematology -- Cardiovascular system -- Renal system -- Inflammatory disorders -- Gastrointestinal pharmacology -- Endocrine pharmacology -- Central nervous system.
  • 2007 CRCnetBASE
    edited by Elka Touitou, Brian W. Barry.
  • 2012 Springer
    editor: Hayden B. Bosworth.
    Enhancing Medication Adherence: The Public Health Dilemma is a comprehensive guide to medication adherence for the healthcare professional. Clinicians and pharmacists alike can benefit from key opinion leader and author Hayden Bosworth's text as he explains the details and causes behind medication nonadherence as well as methods on how healthcare providers can determine if a patient is nonadherent. Additionally, Bosworth discusses various studies, which assess adherence, adherence-related technology, best practices for clinicians and pharmacists, and future directions and recommendations in the field.
  • 2011 WHO
    Introduction to the guidelines. Purpose, target and scope -- Background -- A dual obligation, a quadruple imperative -- Indispensability of controlled medicines in contemporary medical practices -- Safety of controlled medicines -- Current availability -- Impediments to availability, accessibility and affordability -- Why and how to work with this document? -- Guidelines for ensuring balance in national policies on controlled substances. Content of drug control legislation and policy -- Authorities and their role in the system -- Policy planning for availability and accessibility -- Healthcare professionals -- Estimates and statistics -- Procurement -- Other -- Country assessment checklist.
    Also available: Print – 2011
  • 2014 Springer Protocols
    edited by Swati Nagar, Upendra A. Argikar, Donald J. Tweedie.
    Enzyme Kinetics in Drug Metabolism : Fundamentals and Applications -- Fundaments of Enzyme Kinetics -- Different Enzyme Kinetic Models -- Reversible Mechanisms of Enzyme Inhibitors and Resulting Clinical Significance -- Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions -- Multi-Enzyme Kinetics and Sequential Metabolism -- Consideration of the Unbound Drug Concentration in Enzyme Kinetics -- Enzyme Kinetics of Oxidative Metabolism : Cytochromes P450 -- Enzyme Kinetics, Pharmacokinetics, Inhibition, and Regioselectivity of Aldehyde Oxidase -- Enzyme Kinetics of Conjugative Enzymes : PAPS -- Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs) -- Principles and Experimental Considerations for in vitro Transporter Interaction Assays -- Rationalising Under-Prediction of Drug Clearance from Enzyme and Transporter Kinetic Data : from in vitro Tools to Mechanistic Modeling -- The Structural Model for the Mass Action Kinetic Analysis of P-gp Mediated Transport Through Confluent Cell Monolayers -- Systems Biology Approaches to Enzyme Kinetics: Analyzing Network Models of Drug Metabolism -- Variability in Human in vitro Enzyme Kinetics -- Sources of Interindividual Variability -- Case Study 1. Practical Considerations with Experimental Design and Interpretation -- Case Study 2. Practical Analytical Considerations for Conducting in vitro Enzyme Kinetic Studies -- Case Study 3. Application of Basic Enzyme Kinetics to Metabolism Studies : Real Life Examples -- Case Study 4. Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast -- Case Study 5. Deconvoluting Hyperbilirubinemia: Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A, MRP2 or OATP1B1 in Drug Development -- Case Study 6. Drug Transporters: in vitro Solutions for Translatable Outcomes -- Case Study 7. Compiled Aha Moments in Enzyme Kinetics: Authors' Experiences.
  • 2005 CRCnetBASE
    edited by H. John Smith and Claire Simons.
  • 2013 Wiley
    Simon Gaisford and Mark Saunders.
    Basic principles of preformulation studies -- Ionisation constants -- Partitioning affinity -- Solubility -- Dissolution -- Salt selection -- Physical form I : crystalline materials -- Physical form II : amorphous materials -- Stability assessment -- Particle properties -- Powder properties.
  • 2013 Wiley
    by Robert A. Copeland.
    "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
  • 2006 CRCnetBASE
    edited by Ashok Katdare, Mahesh V. Chaubal.
  • 2014 Springer
    William H. Eaglstein.
    "This book explains the Food and Drug Administration (FDA) as an institution and provides understanding of its nomenclature, societal role, policies, goals and challenges. While many readers will have some knowledge of the FDA, few have an appreciation of the many specific areas of FDA authority. The FDA for Doctors is not for those looking for detailed instruction on dealing with the FDA or its operations. Rather, it is written by a doctor with doctors in mind, with the hope that the information in this book will make physicians, and other readers, more thoughtful and insightful, especially with regards totherapeutics and the many broad societal issues underlying FDA's activities. With over 40 years of experience as a clinical investigator in many trials done for FDA registration, the author has been a member of and chaired an FDA advisory committee, and has been a consultant to several divisions of the FDA. He has also had the opportunity to serve on the U.S. Senate Labor Committee, helping with its FDA oversight activities. In addition to a long academic medical career the author has been a consultant to and a full time employee of drug and device companies"--Back cover.
  • 2013 Wiley
    edited by Neal M. Davies, Jaime A. Yanez.
    More and more dietary supplements contain flavonoids. These products are typically viewed as food rather than drug products by regulatory agencies and therefore not subjected to rigorous clinical trials before they are marketed to the general public. As a result, the use of flavonoid-containing supplements presents a potential public health risk. From discovery to therapeutic application, this book is a comprehensive guide to both achiral and chiral flavonoids, enabling researchers to perform essential preclinical and clinical pharmacokinetics studies in order to ensure the efficacy of flavonoids marketed for therapeutic use. Moreover, the book examines the safety and toxicology of flavonoids as well as flavonoid-drug interactions. With contributions from a multidisciplinary team of leading researchers, Flavonoids Pharmacokinetics reviews and synthesizes the most recent research findings and results from preclinical and clinical studies. The book begins with a comprehensive overview of polyphenols and flavonoids. Next, the book covers: methods of analysis of achiral flavonoids. Preclinical pharmacokinetic of flavonoids. Toxicology and safety of flavonoids. Methods of analysis for chiral flavonoids. Clinical pharmacokinetics of flavonoids Flavonoids and drug interactions Throughout the book, the authors provide examples that demonstrate the use of pharmacokinetics concepts during the preclinical and clinical drug development process. Flavonoid Pharmacokinetics is written for pharmaceutical, food, and nutritional scientists and students, offering the tools they need to thoroughly analyze and test flavonoids and flavonoid-containing supplements to ensure their safety and efficacy.
  • 2012 Springer
    Robert O. Williams, Alan B. Watts, Dave A. Miller, editors.
    1. Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs / Stephanie Bosselmann and Robert O. Williams III -- 2. Optimizing the Formulation of Poorly Water-Soluble Drugs / Kevin P. O'Donnell and Robert O. Williams III -- 3. Solid-State Techniques for Improving Solubility / Justin R. Hughey and Robert O. Williams III -- 4. Mechanical Particle-Size Reduction Techniques / Javier O. Morales, Alan B. Watts, and Jason T. McConville -- 5. Solubilized Formulations / Feng Zhang and James C. DiNunzio -- 6. Injectable Formulations of Poorly Water-Soluble Drugs / Michael P. Boquet and Dawn R. Wagner -- 7. Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs / Ping Gao -- 8. Structured Development Approach for Amorphous Systems / Navnit Shah, Harpreet Sandhu, Duk Soon Choi, Oskar Kalb, Susanne Page, and Nicole Wyttenbach -- 9. Melt Extrusion / James C. DiNunzio, Feng Zhang, Charlie Martin, and James W. McGinity -- 10. Spray-Drying Technology / Dave A. Miller and Marco Gil -- 11. Pharmaceutical Cryogenic Technologies / Wei Yang, Donald E. Owens III, and Robert O. Williams III -- 12. Precipitation Technologies for Nanoparticle Production / Jasmine M. Rowe and Keith P. Johnston -- 13. Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs / Justin R. Hughey and James W. McGinity -- 14. Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs / Zedong Dong and Hasmukh Patel.
  • 2006
    edited by Louise Hill Curth.
    Status: Not Checked OutLane Catalog Record
    London apothecaries and other medical retailers / Patrick Wallis -- Medical advertising in the popular press / Louise Hill Curth -- Accessing drugs in the eighteenth century regions / Steve King -- "The doctor's shop" / Hilary Marland -- From "bespoke" to "off-the-peg" / Stuart Anderson -- "A cascade of medicine" / Judy Slinn.
  • 2007 CRCnetBASE
    edited by Paul F. Predki.
    High-throughput gene cloning using the Gateway technology / Scott N. Peterson ... [et al.] -- Protein expression for microarrays / Harry H. Yim, Thomas G. Chappell, and Steven H. Harwood -- Emerging trend: cell-free protein expression / Federico Katzen and Wieslaw Kudlicki -- The critical role of surface chemistry in protein microarrays / Athena Guo and X.-Y. Zhu -- Fabrication of sol-gel-derived protein microarrays for diagnostics and screening / Nicholas Rupcich and John D. Brennan -- Printing and QC of functional protein microarrays / Dee Shen, Fang X. Zhou, and Barry Schweitzer -- Protein engineering for surface attachment / Aparna Girish, Grace Y. J. Chen, and Shao Q. Yao -- Protein in situ arrays through cell-free protein synthesis / Mingyue He ... [et al.] -- Fluorescent detection methods for protein microarrays / Steven Roman and Scott Clarke -- Functional analysis of protein interactions using surface plasmon resonance-based microarrays / Alan McWhirter and Stefan Löfås -- Leaving the surface behind: at the intersection of protein microarrays and mass spectrometry / Darrell P. Chandler ... [et al.] -- High-resolution label-free detection applied to protein microarray research / Lance G. Laing and Brian Cunningham -- Studying protein-protein interactions with protein microarrays: rapid identification of 14-3-3 protein binding partners / Jun-ichi Satoh -- A combined force of chemical genetics and protein microarrays / Heng Zhu and Jing Huang -- Antibody profiling for protein drug development and clinical development / Steve H. Herrmann -- Humoral response profiling using protein microarrays / Arun Sreekumar ... [et al.] -- DNA interactions with arrayed proteins / Marina Snapyan and Vehary Sakanyan -- G protein-coupled receptor microarrays for drug discovery / John Salon ... [et al.] -- Kinase substrate identification using yeast protein microarrays / Geeta Devgan and Michael Snyder -- Protein microarray image analysis / Minzi Ruan -- The analysis of protein arrays / Brad Love -- Evaluating precision and recall in functional protein arrays / Keith Robison -- Visualization of protein microarray data / Kevin Clancy.
  • 2012 Springer
    Juergen Siepmann, Ronald A. Siegel, Michael J. Rathbone, editors.
  • 2014 Springer
    Francesco Chiappelli.
    Fundamental Implications for Clinical Practice -- Translational Effectiveness in the Context of Translational Science -- Comparative Effectiveness Analysis and Evidence-Based Decisions -- Methodology I: The Best Available Evidence -- Methodology II: Sampling and Assessment of the Evidence -- Methodology III: Systematic Evaluation of the Statistical Analysis: Data Analysis in Research Synthesis -- Optimizing Clinical Practice-Based Patient-Centered Outcomes Research -- Getting and Understanding Data -- Obtaining Data -- Describing and Analyzing Data -- Translational Effectiveness Analysis -- Optimizing Clinical Outcomes by Individualizing Observations -- Evaluation in Patient-Centered Outcomes Research -- Translational Effectiveness in Practice-Based Patient-Centered Outcomes Research.
  • 2010 Springer
    by Gopal B. Saha.
    Established as a classic text on nuclear chemistry and pharmacy, 'Fundamentals of Nuclear Pharmacy' has been thoroughly revised and now includes new information covering innovations in imaging technology and clinical applications in the field.
  • 2013 Springer
    Ijeoma F. Uchegbu, Andreas G. Schätzlein, Woei Ping Cheng, Aikaterini Lalatsa, editors.
    Nanoscience and nanotechnology overview -- Liposome preparation and characterization -- Solid polymeric nanoparticles -- Lipid nanoparticles -- Polymeric vesicles -- Low molecular weight amphiphile micelles -- Polymeric micelles -- Niosomes -- Quantum dots -- Magnetic particles -- Drug nanoparticles -- Polymeric pro-drugs -- Therapeutic Applications of pharmaceutical nanosystems -- Drug solubilisation -- Gene therapy -- Chemotherapy -- Tissue engineering -- Anti-infectives -- Vaccination -- Anti-arthritic drugs -- Imaging agents -- Commercial exploitation of pharmaceutical nanosystems -- Future perspectives -- Multiple Choice -- Problem Sets -- Case Studies -- Suggested Reading.
  • 2015 Wiley
    edited by Peter J.H. Scott.
  • 2008 CRCnetBASE
    editors, Brett A. Lidbury and Suresh Mahalingam.
    A perspective on the future clinical impact of genetic diagnosis and gene-based drug therapies for patient health / Julian W. Tang -- Virally-encoded microRNA (miRNA): candidates for gene silencing / Ralph A. Tripp ... [et al.] -- Development of gene profile-responsive antisense agents / Sergei A. Kazakov and Brian H. Johnston -- Gene profiles in drug development: applications in target identification, biomarker discovery, and compound characterization / Eric A.G. Blomme and Dimitri Semizarov -- Gene profiles and cancer / Beverly A. Teicher -- RNA viruses and RNA-based drugs: a perfect match for RNA delivery and the identification of candidate therapeutic target inflammatory molecules / Brett A. Lidbury ... [et al.] -- Ethical considerations for a genetic future in diagnosis and drug development / Lexie Brans and Brett A. Lidbury.
  • 2014
    Jeremy A. Greene.
    Status: Not Checked OutLane Catalog Record
    Generic drugs are now familiar objects in clinics, drugstores, and households around the world. We like to think of these tablets, capsules, patches, and ointments as interchangeable with their brand-name counterparts: why pay more for the same? And yet they are not quite the same. They differ in price, in place of origin, in color, shape, and size, in the dyes, binders, fillers, and coatings used, and in a host of other ways. Claims of generic equivalence, as physician-historian Jeremy Greene reveals, are never based on being identical to the original drug in all respects, but in being the same in all ways that matter. How do we know what parts of a pill really matter? Decisions about which differences are significant and which are trivial in the world of therapeutics are not resolved by simple chemical or biological assays alone. Questions of therapeutic similarity and difference are also always questions of pharmacology and physiology, of economics and politics, of morality and belief. Greene chronicles the social, political, and cultural history of generic drugs, narrating the evolution of the generic drug industry from a set of mid-twentieth-century "schlock houses" and "counterfeiters" into an agile and surprisingly powerful set of multinational corporations in the early twenty-first century. The substitution of bioequivalent generic drugs for more expensive brand-name products is a rare success story in a field of failed attempts to deliver equivalent value in health care for a lower price. Greene's history sheds light on the controversies shadowing the success of generics: problems with the generalizability of medical knowledge, the fragile role of science in public policy, and the increasing role of industry, marketing, and consumer logics in late-twentieth-century and early twenty-first century health care.
  • 2014 CRCnetBASE
    edited by Leon Shargel, Isadore Kanfer.
    "This book collects in-depth discussions from more than 30 noted specialists on topics such as quality control, experimental formulations, pharmaceutical ingredients, conventional and modified-release products, and bioequivalence. It considers key elements in the formulation of generic drug products including the availability of raw materials and chemical purity. It contains new chapters on experimental formulation development, and the relationship between the FDA and the United States Pharmacopeia"--Provided by publisher.
  • 2014 ScienceDirect
    edited by Yihong Yao, Bahija Jallal, Koustubh Ranade.
    Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across all stages of pharmaceutical development with a special focus on personalized health care. This book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, commercialization and much more. It features case studies devoted to the applications of pharmacogenomics, toxicogenomics, and other genetic technologies as they support drug discovery and development. With chapters written by international authorities in industry and academia, this work is a truly unique presentation of the thoughts and approaches that lead to the development of personalized medicine. Intended for all those involved in clinical translational research, this book is the ideal resource for scientists searching for the applications, strategies and successful approaches of translational science in pharmaceutical development. Provides case studies in applications of pharmacodynamic and predictive markers in drug development in oncology, autoimmunity, respiratory diseases and infectious diseases. Shows how to identify potential new therapeutic targets in different diseases and provides examples of potential new disease indications for life cycle management of drugs. Authored by leading international experts from industry and academia.
  • 2005 CRCnetBASE
    Andrew A. Signore, Terry Jacobs.
  • 2003 CRCnetBASE
    edited by Sandy Weinberg.
  • 2001 CRCnetBASE
    Sidney H. Willig.
    Also available: Print – 2001
  • 2005 CRCnetBASE
    John Sharp.
  • 2006 CRCnetBASE
    edited by Stephen P. Denyer, Rosamund M. Baird.
  • 2003 CRCnetBASE
    Timothy M. Crowder ... [et al.].
    Particulate systems: manufacture and characterization -- Sampling and measurement biases -- Particle size descriptors and statistics -- Behavior of particles -- Instrumental analysis -- Methods of particle size measurement and their importance for specific applications (instrument synergy) -- Particle size behavior and physical behavior of a powder -- Clinical effect of pharmaceutical particulate systems.
  • 2014 Springer
    Michelle A. Rudek, Cindy H. Chau, associate eidtors ; William D. Figg, Howard L. McLeod, senior editors.
    There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer. Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs. Road map to anticancer drug development from discovery to NDA submission Discussion of molecular targets and preclinical screening Development and validation of bioanalytical methods Chapters on clinical trial design and phase 0, I, II, III clinical trials Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents Review of the drug development process from both laboratory and clinical perspectives New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development.
  • 2006 CRCnetBASE
    edited by Lisa K. Minor.
  • 2005 CRCnetBASE
    Safaraz K. Niazi.
  • 2001 CRCnetBASE
    edited by Ramakrishna Seethala, Prabhavathi B. Fernandez.
    Also available: Print – 2001
  • 2014 Cambridge
    Henry G.W. Paw, Rob Shulman.
  • 2003 CRCnetBASE
    edited by Beverly J. McCabe, Eric H. Frankel, Jonathan J. Wolfe.
  • 2014 Springer
    Ricardo Munoz... [and others], editors.
    With just over half a decade passing since the first edition of the Handbook of Pediatric Cardiovascular Drugs was published, it remains the only book of its nature to provide health care practitioners with a tool to safely and consistently prescribe and administer cardiovascular drugs in children with cardiac disease. In this new edition, the editors have updated this important resource in collaboration with highly reputed authors. This pocket reference handbook remains tailored to help cardiovascular practitioners meet the daily challenges of caring forpatients, from the newborn to the young adult, with cardiac disease. In addition to providing an extensive review of all cardiovascular medications, the Handbook of Pediatric Cardiovascular Drugs, 2nd Edition also discusses the information required to assist caregivers in their daily clinical practice. Physicians, fellows, residents, nurse practitioners, physician assistants, pharmacists, nurses and other practitioners alike will find this handbook to be an essential resource for drug therapy in complex and high-risk patients with acquired and congenital heart disease.
  • 2014 CRCnetBASE
    edited by Ioannis S. Vizirianakis.
    This book compiles multidisciplinary efforts to conceptualize the environment in research and clinical setting that creates the fertile ground for the practical utility of personalized medicine decisions and also enables clinical pharmacogenomics for establishing pharmacotyping in drug prescription. Its covers innovative drug formulations and nanotheranostics, molecular imaging and signatures, translational nanomedicine and informatics, stem cell therapy approaches, modeling and predictability of drug response, pharmacogenetics-guided drug prescription, pediatric drug dosing, pharmacovigila.
  • 2005 CRCnetBASE
    edited by Dilip M. Parikh.

Access restricted to Stanford community

Shortcut to Licensed Content

Lane Gateway to Licensed Content

TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.

What is it?

Lane Gateway to Licensed Content

Bookmark on Other Websites

Bookmark on Lane

  • TO INSTALL, RIGHT CLICK this button.
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page
TO INSTALL, RIGHT CLICK this button.

What is it?

A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.

Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.

MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.

Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.

Includes cited reference searching, citation maps, and an analyze tool.

Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.

Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.

Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.

Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.

In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.

A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.

A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.

Over 10,000 notes outline the status of specific infections within each country.

Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.

Provides online, full-text access to Springer's journal titles as well as journals from other publishers.

Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.

Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.
CONTACT US